PDF icon Download PDF
Dtsch Med Wochenschr 2002; 127(40): 2076-2078
DOI: 10.1055/s-2002-34517
CME
© Georg Thieme Verlag Stuttgart · New York

Polyneuropathie - Therapie

Polyneuropathy - TreatmentB. Schlotter-Weigel, D. E. Pongratz
  • 1Friedrich-Baur-Institut an der Neurologischen Klinik LMU München
Further Information

Publication History

eingereicht: 6.5.2002

akzeptiert: 31.7.2002

Publication Date:
02 October 2002 (online)

Also available ateRef
  Permissions and Reprints
Preview

Glossar: AMA = antimitochrondriale AK; ANA = antinukleäre Antikörper; ANCA = antineutrophile cytoplasmatische Antikörper; AK = Antikörper; CIDP = chronische inflammatorisch-demyelinisierende Polyradikulopathie; ds-DNS-AK = doppelsträngige DNS-Antikörper; GBS = Guillain-Barré-Syndrom; GM1-/GM2-/GQ1b-/Gd1a-AK = Gangliosid AK; HNPP = Hereditäre Neuropathie mit Neigung zu Druckparesen; IVIG = intravenöse Immunglobulingabe; MAG = Myelin-assoziiertes Glykoprotein; MGUS = monoklonale Gammopathie unbestimmter Signifikanz; MMN = Multifokale motorische Neuropathie; MRT = Magnetresonanztomographie; PNP = Polyneuropathie; PMP = peripheres Myelin-Protein; SGPG = Sulfoglucuronyl-Paragloboside

Literatur

  • 1 Apfel S C, Kessler J A, Adornato B T, Litchy W J, Sanders C, Rask C A. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy.  Neurology. 1998;  3 695-702
    Search in Google Scholar
  • 2 Barohn R J, Kissel J T, Warmolts J R, Mendell J R. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria.  Arch Neurol. 1989;  46 878-884
    Search in Google Scholar
  • 3 Blume G, Pestronk A, Goodnough L T. Anti-MAG antibody associated with monthly plasma exchange and IV cyclophosphamide.  Neurology. 1995;  45 1577-1580
    Search in Google Scholar
  • 4 Boulton A JM, Levin S, Comstock J A. A multicenter trial of the aldose reductase inhibitor tolrestat in patients with symptomatic diabetic neuropathy.  Diabetologica. 1990;  33 431-437
    Search in Google Scholar
  • 5 Boulton A JM, Ziegler D, Scarpello J. et al . A multicentre double-blind trial of gamolenic acid in diabetic peripheral sensorimotor neuropathy.  Diabetologica. 1997;  40 (Suppl 1) 117
    Search in Google Scholar
  • 6 Chalk C H. Acquired peripheral neuropathy.  Neurologic clinics. 1997;  15 501-521
    Search in Google Scholar
  • 7 Cook D, Dalakas M, Galdi A. et al . High dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy.  Neurology. 1990;  40 212-241
    Search in Google Scholar
  • 8 De Carvalho M, Luis M L. Relapsing chronic low-dose corticosteroid-responsive multifocal motor neuropathy with conduction block.  Electromyogr Clin Neurophysiol. 1997;  37 95-97
    Search in Google Scholar
  • 9 Donada C, Crucitti A, Donadon V, Chemello L, Alberti A. Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia.  Blood. 1998;  92 2983-2984
    Search in Google Scholar
  • 10 Donaghy M, Mills K R, Boniface S J, Simmons J, Wright L, Gregson N, Jacobs J. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin.  J Neurol Neurosurg Psychiatry. 1994;  57 778-783
    Search in Google Scholar
  • 11 Dyck P J, O’Brien P, Swanson C, Low P, Duabe J. Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy.  Neurology. 1985;  35 1173-1176
    Search in Google Scholar
  • 12 Dyck P J, Low P A, Windebank A J. et al . Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.  N Engl J Med. 1991;  325 1482-1486
    Search in Google Scholar
  • 13 Fauci A S, Haynes B F, Katz P, Wolf S M. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.  Ann Intern Med. 1983;  98 76-85
    Search in Google Scholar
  • 14 Feldman E L, Bromberg M B, Albers J W, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy.  Ann Neurol. 1991;  30 397-401
    Search in Google Scholar
  • 15 Graus F, Vega F, Delattre J Y. et al . Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal antibodies.  Neurology. 1992;  42 536-540
    Search in Google Scholar
  • 16 Haas D C, Tatum A H. Plasmapheresis alleviates neuropathy accomanying IgM anti-myelin-associated glycoprotein paraproteinemia.  Ann Neurol. 1988;  23 394-396
    Search in Google Scholar
  • 17 Hartung H P, Pollard J D, Harvey G K, Toyka K V. Immunopathogenesis and treatment of the Guillain-Barré-Syndrom, part I.  Muscle Nerve. 1995a;  18 137-153
    Search in Google Scholar
  • 18 Hartung H P, Pollard J D, Harvey G K, Toyka K V. Immunopathogenesis and treatmet of the Guillain-Barré-Syndrom, part II.  Muscle Nerve. 1995b;  18 154-164
    Search in Google Scholar
  • 19 Jensen T S. Anticonvulsants in neuropathic pain: rationale and clinical evidence.  Eur J Pain. 2002;  6(Suppl) 61-68
    Search in Google Scholar
  • 20 Johannsson B L, Borg K, Fernquist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type I diabetes mellitus.  Diabet Med. 2000;  17 181-189
    Search in Google Scholar
  • 21 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy.  Neurology. 1992;  42 506-509
    Search in Google Scholar
  • 22 Langford C A, Talar-Williams C, Barron K S, Sneller M C. A staged approach to the treatment of Wegener’s granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance.  Arthritis Rheum. 1999;  42 2666-2673
    Search in Google Scholar
  • 23 Langford C A. Management of systemic vasculitis.  Best Pract Res Clin Rheumatol. 2001;  15 1134-1139
    Search in Google Scholar
  • 24 Mahattanaku L W, Crawford T O, Griffin J W, Goldstein J M, Cornblath D R. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.  J Neurol Neurosurg Psychiatry. 1996;  60 185-187
    Search in Google Scholar
  • 25 Mariette X, Chastang C, Clavelou P. et al . A randomised trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM.  J Neurol Neurosurg Psychiatry. 1997;  63 28-34
    Search in Google Scholar
  • 26 Metzler C, Loew-Friedrich & block;, Reinhold-Keller E, Fink C, Gross W L. Maintenance of remission with leflunomide in Wegener’s granulomatosis.  Arthritis Rheum. 1999;  42 1466
    Search in Google Scholar
  • 27 Misiani R, Bellavista P. Mixed cryoglobulinemia. A guide to drug treatment.  Clin Immunother. 1996;  5 115-121
    Search in Google Scholar
  • 28 Moll J WB, Henzen-Logmans S C, van der Meche F GA, Vecht C HJ. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration.  J Neurol Neurosurg Psychiatry. 1993;  56 112
    Search in Google Scholar
  • 29 Nobile-Orazio E, Baldini L, Barbieri S. et al . Treatment of patients with neuropathy and anti-MAG IgM M-proteins.  Ann Neurol. 1988;  24 94-97
    Search in Google Scholar
  • 30 Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude F L. Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.  J Am Soc Nephrol. 1999;  10 1965-1971
    Search in Google Scholar
  • 31 Ogawa T, Taguch T, Tanaka Y, Ikeguchi K, Nakano I. Intravenous immunoglobulin therapy for diabetic amyotrophy.  Intern Med. 2001;  40 349-352
    Search in Google Scholar
  • 32 Oksenhendler E, Chevret S, Léger J M. et al . Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy.  J Neurol Neurosurg Psychiatry. 1995;  59 243-247
    Search in Google Scholar
  • 33 Rasmussen N JD, Abramowicz D, Andrassy K, Bacon P A, Cohen Tervaert J W, Dadoniené J. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials.  Clin Exp Immunol. 1995;  101 (Suppl) 101
    Search in Google Scholar
  • 34 Richter C, Schnabel A, Csernok E, de Groot K, Reinhold-Keller E, Gross W L. Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin.  Clin Exp Immunol. 1995;  101 2-7
    Search in Google Scholar
  • 35 The Diabetes Control Complications Trial Research Group . The effect of intensive diabetes therapy on the development and progression of neuropathy.  Ann Intern Med. 1995;  122 561-568
    Search in Google Scholar
  • 36 Van den Berg L H, Lockhorst H, Wokke J HJ. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy.  Neurology. 1997;  48 1135
    Search in Google Scholar
  • 37 Van der Meché F GA, Schmitz P IM. and the Dutch Guillain-Barré Study Group . A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré-Syndrome.  N Engl J Med. 1992;  236 1123-1129
    Search in Google Scholar
  • 38 Van der Meché F GA, van Doom P A. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.  Ann Neurol. 1995;  37 (suppl) 914-931
    Search in Google Scholar
  • 39 van Doom P A, Brand A, Strengers P F, Meulstee J, Vermeulen M. Highdose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-conrolled crossover study.  Neurology. 1990;  40 209-212
    Search in Google Scholar
  • 40 Ziegler D, Hanefeld M, Ruhnua K J. et al . Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A 3-week multi-center randomized controlled trial (ALADIN Study).  Diabetologica. 1995;  38 1425-1433
    Search in Google Scholar
  • 41 Kissel J T, Mendell J R. Vasculitic Neuropathy.  Neurol Clin. 1992;  10(3) 761-781
    Search in Google Scholar

Dr. med. Beate Schlotter-Weigel

Friedrich-Baur-Institut an der Neurologischen Klinik LMU München

Ziemssenstraße 1

80336 München

Phone: 089/51607470

Fax: 089/51607402

Email: b.schlotter@fbs.med.uni-muenchen.de